Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) took another step towards commercializing its lead drug ATB-346 with the hiring of a new executive team member.
Seasoned pharmaceutical executive Dr Rami Batal is joining the Toronto-based company as its new senior vice president, commercial strategy.
With experience in pharmaceutical development and commercialization of pain drugs globally, Batal helped guide in-licensing on behalf of major pharma companies.
READ: Antibe Therapeutics running largest number of sites for any clinical trial in Canada in ATB-346 study
Batal is tasked with leveraging Antibe’s recent business development initiatives, which include its recent health economics study and the ongoing comprehensive market opportunity assessment and payor study.
A key aspect of the role involves providing partners with a robust commercial strategy package, including an in-depth framework on positioning, launch-planning and reimbursement, according to Antibe.
“This new role will help us maximize the value of ATB-346 as we ramp up partnering discussions for the larger markets,” said Antibe’s CEO Dan Legault in a statement Monday.
“Rami’s deep experience in commercialization of analgesics will enable us to fully capture and communicate the drug’s commercial potential to our partners. We are delighted to welcome him to our growing team.”
ATB-346 targets acute and chronic pain associated with osteoarthritis. Currently, in Phase 2 trials, the drug is a naproxen-derivative that has been shown to deliver pain relief with significantly less gastrointestinal damage than typical NSAID usage.
Antibe also announced that it promoted Scott Curtis to the role of executive vice president, where he will be responsible for coordinating corporate activities as the company’s business development initiatives take flight this year.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas